rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    GANX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686

      IAPRD late-breaking poster shows MDS-UPDRS motor scores remained stable compared to baseline recorded at study entry with no disease progression a...

      Nov 17Business InsiderGANX
      Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know
      Nov 16Yahoo FinanceGANX
      Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update
      Nov 10Yahoo FinanceGANX
      Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
      Nov 5Yahoo FinanceGANX
      Gain Therapeutics appoints Jeanette Weidner as vice president, finance
      Oct 28Investing.comGANX
      Gain Therapeutics to Attend the 2026 Maxim Growth Summit
      Oct 8Yahoo FinanceGANX
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Unitedhealth Group (UNH-N) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailGANX
      H.C. Wainwright Reaffirms Their Buy Rating on Gain Therapeutics (GANX)

      Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailGANX
      BTIG reiterates Buy on Gain Therapeutics stock on trial data
      Oct 5Investing.comGANX
      Gain Therapeutics highlights promising Parkinson’s Phase 1b data

      Detailed price information for Gain Therapeutics Inc (GANX-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailGANX
      Gain Therapeutics reports stable motor scores in Parkinson’s trial
      Oct 1Investing.comGANX
      Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration

      MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants ...

      Oct 1Business InsiderGANX
      Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
      Sep 29Yahoo FinanceGANX
      Gain Therapeutics announces CFO resignation and interim appointment
      Sep 28Investing.comGANX
      Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
      Sep 17Yahoo FinanceGANX
      H.C. Wainwright reiterates Gain Therapeutics stock rating at buy
      Aug 31Investing.comGANX
      Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

      BETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16 in New York City, NY. On-demand Company Presentation Date and Time:

      Aug 25Yahoo FinanceGANX

      This is the newest page. Registered accounts read further back.